Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective
Authors:
- 15 October 2018
- journal article
- research article
- Published by Springer Nature in The AAPS Journal
- Vol. 20 (6) , 109
Abstract
Due to complexities in the structure, function, and manufacturing process of antibody-based therapeutic proteins, comparability assessment for supporting manufacturing changes can sometimes be a...Keywords
This publication has 71 references indexed in Scilit:
- Preclinical Models Used for Immunogenicity Prediction of Therapeutic ProteinsPharmaceutical Research, 2013
- Discovery and mechanism of ustekinumabmAbs, 2011
- Neonatal Fc receptor and IgG-based therapeuticsmAbs, 2011
- Charge variants in IgG1mAbs, 2010
- Structure and function of immunoglobulinsJournal of Allergy and Clinical Immunology, 2010
- Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRnProtein Science, 2009
- Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in miceBiologicals, 2008
- Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changesBiotechnology Advances, 2007
- Effects of protein aggregates: An immunologic perspectiveThe AAPS Journal, 2006
- Human antibody–Fc receptor interactions illuminated by crystal structuresNature Reviews Immunology, 2004